Skadden is advising Revance Therapeutics, while Kirkland & Ellis and Lowenstein Sandler are advising Crown Laboratories on the deal. Crown Laboratories, Inc., a privately held, global...
Crown Laboratories’ $924 Million Merger with Revance Therapeutics
Hildred Capital’s $750 Million Continuation Fund
Lowenstein Sandler represented Hildred Capital in the transaction. Hildred Capital raised $750 million for its continuation fund to extend its ownership of two of its portfolio companies, Hyland’s...